AEM Launches WMO-Compliant Automated Weather Station to Elevate Global Weather Monitoring
13.1.2025 16:00:00 CET | Business Wire | Press release
AEM, the essential source for environmental insights, today announced its WMO-compliant AEM Apex Automated Weather Station (AWS). This state-of-the-art solution sets a new benchmark for precision, reliability, and durability, meeting the strict standards of the World Meteorological Organization (WMO).
Designed to address the toughest challenges in weather monitoring, the WMO-compliant AWS offers unparalleled accuracy and performance for a variety of critical applications, from localized climate research to large-scale weather networks.
Key Benefits of the WMO-Compliant AWS
- Precision Data for Better Decisions: Provides WMO-compliant measurements with strict tolerances to support critical applications.
- Seamless Global Collaboration: Enables efficient data sharing with regional and global partners, fostering enhanced coordination for monitoring and forecasting.
- Reliability in Extreme Conditions: Built to deliver continuous, accurate data with minimal maintenance, even in the most demanding environments.
- Future-Proof Design: A scalable, standards-compliant system that evolves with the changing needs of users.
Advanced Specifications
The AEM Apex AWS incorporates cutting-edge components and technology, including:
- Wind Monitoring: Ultrasonic sensors with wind direction accuracy of < 2° and wind speed accuracy of ± 0.2 m/s.
- Rain Measurement: Precision load cell technology with accuracy of ± 0.1 mm or 1% at lower rainfall rates.
- Solar Monitoring: Secondary standard pyranometer for high-quality solar radiation data.
- Temperature, Humidity, and Pressure Monitoring: Air temperature accuracy up to ± 0.1 K and barometric pressure accuracy of ± 0.15 hPa.
- Communication Capabilities: Ser[LOG] data logger with 4G modem, TLS 1.3 security, and versatile communication protocols like Modbus, Ethernet, and SMS.
Serving Diverse Markets Across the Public and Private Sector
The WMO- and ICAO- (International Civil Aviation Organization) compliant AWS serves markets across weather monitoring and forecasting. National Meteorological and Hydrological Services can enhance their national weather networks with precise, reliable solutions. Regional Mesonets and research institutions will improve their local forecasting and climate monitoring capabilities, while private sector organizations in aviation, energy, and utilities can optimize operations, ensure safety, and make data-driven decisions using the most precise weather data available.
AEM’s Commitment to Weather Monitoring Excellence
AEM continues to set the standard in weather and environmental monitoring by offering end-to-end solutions, from network design and installation to software and maintenance. Trusted by government agencies, meteorological services, and communities worldwide, AEM has deployed thousands of systems for severe weather, wildfire, and flood risk management.
The AEM Apex AWS integrates seamlessly with AEM’s Elements® 360, a powerful decision-support application designed to unify and simplify data sharing, enhance response coordination, and ensure the safety of communities worldwide.
To learn more about AEM’s WMO-compliant Automated Weather Station and broader weather monitoring solutions, visit https://aem.eco.
About AEM
AEM is combining global technology leaders to empower communities and organizations to survive and thrive in the face of escalating environmental risks. By deploying intelligent sensing networks, operating a secure and scalable data management infrastructure, and delivering high-value analytics through a suite of end-user applications, AEM serves as the essential source for environmental insights. These technologies enable positive outcomes, helping reduce environmental impact and creating a safer world. For more information, visit https://aem.eco/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113755485/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom